Abrinica, Clyde .

HRN: 27-22-75  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/24/2025
CEFTAZIDIME 1GM (VIAL)
09/24/2025
10/01/2025
IV
385mg
Q8h
PCAP C
Waiting Final Action 
09/30/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
09/30/2025
10/14/2025
IV
70mg
Q12H
Hospital Acqiured Pneumonia, UTI
Waiting Final Action 
09/30/2025
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
09/30/2025
10/14/2025
IV
92mg As Loading Dose; 70mg As Maintenance
Q24H
Hospital Acquired Pneumonia; UTI
Waiting Final Action 
11/02/2025
MUPIROCIN 2%, 15G (TUBE)
11/02/2025
11/08/2025
TOPICAL
2%
BID
Infected Post-op Site
Checking Final Appropriateness 
11/03/2025
CIPROFLOXACIN 500MG (TAB)
11/03/2025
11/10/2025
NGT
80mg/pptab
Q12
Pseudomonas Aeroginosa Infection
Checking Final Appropriateness 
11/04/2025
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
11/04/2025
11/11/2025
NGT
4ml
TID
Intestinal Amoebiasis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: